| 1. |
Luppi F, Spagnolo P, Cerri S, et al.The big clinical trials in idiopathic pulmonary fibrosis.Curr Opin Pulm Med, 2012, 18:428-432.
|
| 2. |
American Thoracic Society; European Respiratory Society.American Thoracic Society:idiopathic pulmonary fibrosis:diagnosis and treatment:international consensus statement.AmJRespir Crit Care Med, 2000, 161:646-664.
|
| 3. |
Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management.AmJRespir Crit Care Med, 2011, 183:788-824.
|
| 4. |
Chambers RC.Procoagulant signalling mechanisms in lung inflammation and fibrosis:novel opportunities for pharmacological intervention? BrJPharmacol, 2008, 153:S367-S378.
|
| 5. |
Navaratnam V, Fogarty AW, McKeever T, et al.Presence ofaprothrombotic state in people with idiopathic pulmonary fibrosis:a population-based case-control study.Thorax, 2014, 69:207-215.
|
| 6. |
Sode BF, Dahl M, Nielsen SF, et al.Venous thromboembolism and risk of idiopathic interstitial pneumonia:a nationwide study.AmJRespir Crit Care Med, 2010, 181:1085-1092.
|
| 7. |
Sprunger DB, Olson AL, Huie TJ, et al.Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.Eur Respir J, 2012, 39:125-132.
|
| 8. |
Kubo H, Nakayama K, Yanai M, et al.Anticoagulant therapy for idiopathic pulmonary fibrosis.Chest, 2005, 128:1475-1482.
|
| 9. |
Noth I, Anstrom KJ, Calvert SB, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.AmJRespir Crit Care Med, 2012, 186:88-95.
|
| 10. |
Daniels CE, Lasky JA, Limper AH, et al.Imatinib-IPF Study Investigators.Imatinib treatment for idiopathic pulmonary fibrosis:Randomized placebo-controlled trial results.AmJRespir Crit Care Med, 2010, 181:604-610.
|
| 11. |
Tomioka H, Kuwata Y, Imanaka K, et al.A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis.Respirology, 2005, 10:449-455.
|
| 12. |
Demedts M, Behr J, Buhl R, et al.IFIGENIA Study Group.High-dose acetylcysteine in idiopathic pulmonary fibrosis.N EnglJMed, 2005, 353:2229-2242.
|
| 13. |
Raghu G, Anstrom KJ, King TE Jr, et al.Idiopathic Pulmonary Fibrosis Clinical Research Network.Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.N EnglJMed, 2012, 366:1968-1977.
|
| 14. |
Briel M, Bassler D, Wang AT, et al.The dangers of stoppingatrial too early.J Bone Joint Surg Am, 2012, 94:56-60.
|
| 15. |
Moorhouse RC, Webb DJ, Kluth DC, et al.Endothelin antagonism and its role in the treatment of hypertension.Curr Hypertens Rep, 2013, 15:489-496.
|
| 16. |
Jain R, Shaul PW, Borok Z, et al.Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin typeAreceptor-mediated production of TGF-β1.AmJRespir Cell Mol Biol, 2007, 37:38-47.
|
| 17. |
Park SH, Saleh D, Giaid A, et al.Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist.AmJRespir Crit Care Med, 1997, 156:600-608.
|
| 18. |
Raghu G, Behr J, Brown KK, et al.ARTEMIS-IPF Investigators.Treatment of idiopathic pulmonary fibrosis with ambrisentan:a parallel, randomized trial.Ann Intern Med, 2013, 158:641-649.
|
| 19. |
Richeldi L, Costabel U, Selman M, et al.Efficacy ofatyrosine kinase inhibitor in idiopathic pulmonary fibrosis.N EnglJMed, 2011, 365:1079-1087.
|
| 20. |
Richeldi L, du Bois RM, Raghu G, et al.INPULSIS Trial Investigators.Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N EnglJMed, 2014, 370:2071-2082.
|
| 21. |
Nakazato H, Oku H, Yamane S, et al.A novel antifibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level.EurJPharmacol, 2002, 446:177-185.
|
| 22. |
Iyer SN, Gurujeyalakshmi G, Giri SN.Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther, 1999, 291:367-373.
|
| 23. |
Iyer SNGG, Gurujeyalakshmi G, Giri SN.Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther, 1999, 289:211-218.
|
| 24. |
Oku H, Shimizu T, Kawabata T, et al.Antifibrotic action of pirfenidone and prednisolone:different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.EurJPharmacol, 2008, 590:400-408.
|
| 25. |
Azuma A, Nukiwa T, Tsuboi E, et al.Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.AmJRespir Crit Care Med, 2005, 171:1040-1047.
|
| 26. |
Taniguchi H, Ebina M, Kondoh Y, et al.Pirfenidone Clinical Study Group in Japan.Pirfenidone in idiopathic pulmonary fibrosis.Eur Respir J, 2010, 35:821-829.
|
| 27. |
Noble PW, Albera C, Bradford WZ, et al.CAPACITY Study Group.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials.Lancet, 2011, 377:1760-1769.
|
| 28. |
King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group.A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N EnglJMed, 2014, 370:2083-2092.
|
| 29. |
Jackson RM, Glassberg MK, Ramos CF, et al.Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.Lung, 2010, 188:115-123.
|
| 30. |
Zisman DA, Schwarz M, Anstrom KJ, et al.Idiopathic Pulmonary Fibrosis Clinical Research Network.A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.N EnglJMed, 2010, 363:620-628.
|
| 31. |
Han MK, Bach DS, Hagan PG, et al.IPF net Investigators.Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and rightsided ventricular dysfunction.Chest, 2013, 143:1699-1708.
|
| 32. |
King TE Jr, Brown KK, Raghu G, et al.BUILD-3:a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.AmJRespir Crit Care Med, 2011, 184:92-99.
|
| 33. |
King TE Jr, Behr J, Brown KK, et al.BUILD-1:a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.AmJRespir Crit Care Med, 2008, 177:75-81.
|
| 34. |
Raghu G, Million-Rousseau R, Morganti A, et al.MUSIC Study Group.Macitentan for the treatment of idiopathic pulmonary fibrosis:the randomised controlled MUSIC trial.Eur Respir J, 2013, 42:1622-1632.
|
| 35. |
Corte TJ, Keir GJ, Dimopoulos K, et al.BPHIT Study Group.Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.AmJRespir Crit Care Med, 2014, 190:208-217.
|
1/5
WeChat